Loading..
  • SynAct Pharma logoSVE
  • SynAct Pharma logoENG
  • About us
    • The Company in brief
    • Vision
    • Mission
    • History
    • Organisation
    • Collaborations and Partnerships
  • Our Science
    • Resolving Inflammation
    • The Melanocortin System and Inflammation
    • SynAct’s Technology – Selective Melanocortin Stimulation
    • Scientific Advisory Board
  • Pipeline
    • Pipeline Overview
    • The AP1189 Development Program
      • Rheumatoid Arthritis
      • Membranous Nephropathy
      • Virus Induced Respiratory Insufficiency
    • Peptide Agonists
      • TXP-11
    • Ongoing clinical studies
  • Investors
    • Capital Markets Day 2023
    • Listing Nasdaq 2022
    • Rights Issue 2022
    • Word from the CEO
    • Financial Reports
    • Investment highlights
    • Presentations
    • The Share
      • Share price development
      • Ownership Structure
      • Insiders
      • Share Capital Development
    • Analyst Coverage
    • Calendar
    • Press Releases
    • Prospectuses
  • Governance
    • General Meetings
    • Corporate Governance Report
    • Nomination Committee
      • Nomination Committee 2023
    • Board of Directors
      • Remuneration Committee
      • Audit Committee
      • R&D Committee
    • Management
    • Auditor
    • Articles of Association
    • Code of Conduct
  • Media
    • Press Releases
    • Synact in Media
    • Image Bank
    • Subscribe
  • Contact

Calendar

2021
  • Upcoming events
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • All years
  • 12
    Feb
    February 12, 2021
    Bokslutskommuniké, 2020
    Add to calendar
  • 22
    Mar
    March 22 - March 25, 2021
    Participation at Bio Europe
    Add to calendar
  • 05
    May
    May 5, 2021
    Interim report Q1 2021
    Add to calendar
  • 05
    May
    May 5, 2021
    Participation at The Kempen & Co Life Sciences Conference
    Add to calendar
  • 21
    May
    May 21, 2021
    Annual general Meeting 2021 / Årsstämma 2021
    Add to calendar
  • 25
    May
    May 25, 2021
    ABGSC Life Science Summit
    Add to calendar
  • 27
    Aug
    August 27, 2021
    Interim report Q2 2021
    Add to calendar
  • 25
    Oct
    October 25 - October 27, 2021
    Bio Europe
    Add to calendar
  • 09
    Nov
    November 9, 2021
    ACR Convergence 2021
    Add to calendar
  • 12
    Nov
    November 12, 2021
    Interim report Q3 2021
    Add to calendar
  • 07
    Dec
    December 7, 2021
    Sedermeradagen, Villa Copenhagen
    Add to calendar
  • 08
    Dec
    December 8, 2021
    ABGSC Investor Days
    Add to calendar
  • Investors
    • Capital Markets Day 2023
    • Listing Nasdaq 2022
    • Rights Issue 2022
    • Word from the CEO
    • Financial Reports
    • Investment highlights
    • Presentations
    • The Share
      • Share price development
      • Ownership Structure
      • Insiders
      • Share Capital Development
    • Analyst Coverage
    • Calendar
    • Press Releases
    • Prospectuses
Torbjørn Bjerke
Torbjørn Bjerke
Chief Executive Officer
+46 727 44 41 58
[email protected]com
Patrik Renblad, MSc.
Patrik Renblad, MSc.
Chief Financial Officer
+4670 747 97 68
[email protected]

About Synact Pharma

SynAct Pharma is a clinical stage biotechnology company focused on resolving inflammation with melanocortin biology. Selective activation of the melanocortin system can help the immune system resolve excessive or chronic inflammation.

  • Privacy Policy
  • Cookies

Explore our Website

  • About us
  • Our Science
  • Pipeline
  • Investors
  • Governance
  • Media
  • Contact
  • LinkedIn

Subscribe